Beijing Konruns Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

159.21

P/S

8.14

EPS

0.27

Div Yield, %

0.70%

Shrs. gr., 5y

-0.46%

Rev. gr., 5y

-4.99%

Revenues

825m

-10.28%

Net income

42m

-71.94%

CFO

172m

-13.60%

Dividend

Jul 04, 20240.3 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and KC1036. The company was founded in 2003 and is headquartered in Beijing, China.

URL

http://www.konruns.cn/

IPO date

Aug 27, 2018

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT